RxTrials Institute Drug Pipeline Alert

Callisto Pharmaceuticals has received interim data from the company’s ongoing, open-label Phase II clinical trial of Atiprimod for treatment of low- to intermediate-grade neuroendocrine carcinoma.

Overall, the results suggest that Atiprimod is an active and well-tolerated drug in the treatment of advanced carcinoid cancer, the company said.

The analysis measured tumor response, symptom relief and side effects. Details of this analysis will be presented at the 44th annual meeting of the American Society of Clinical Oncology, which will be held in Chicago May 30 through June 3.